J&J agreed to pay $158 million to stop a trial in Texas. Though appeals are pending, it lost in South Carolina ($327 million), Louisiana ($258 million) and Arkansas ($1.2 billion). The company is negotiating with the federal government and reports suggest it might pay as much as $2.2 billion. Though concepts might transcend state lines, evidence does not always make it across. But in Pennsylvania, the Commonwealth Court essentially agreed with J&J attorney Edward Posner of Drinker Biddle who argued on May 16 in the Philadelphia hearing that the commonwealth had shown “a complete and total failure” to prove its case.<\/p>\n
Among the J&J suits, this one is the hardest one for me to understand. Pennsylvania is where whistle-blower Allen Jones worked when he discovered the improper diversion of funds by J&J to bring Texas’ Mental Health Director, Dr. Stephen Shon, to PA to hawk his TMAP program. That was the beginning of the unraveling of J&J’s scheme to induce state government systems to preferentially use their drug [Risperdal]. When Jones was fired for investigating, he successfully sued in Psennsylvania and then filed his whistle-blower suit in Texas against J&J which was settled in January for $158 M – setting off a cascade of suits in other States with escalating awards. The Pennsylvania suit was thrown out after a partial trial in 2010, and now has not been successful on the appeal of that dismissal. In spite of large settlements in South Carolina, Louisiana, and Arkansas [all of which are being appealed], the only case they’ve actually paid on is in Texas where they settled during the trial in the face of damning testimony from medical experts – though a large $2.2 B Federal settlement looms in the near future. Having heard the evidence in the Texas Trial, it’s hard to imagine that they were behaving any better in Pennsylvania. The only thing I can figure is that Jones’ discovery came early and they hadn’t yet gotten their scam going…<\/div>\n","protected":false},"excerpt":{"rendered":"
Judges Uphold Dismissal of Pennsylvania Risperdal Suit Against Johnson & Johnson Fox Business News by Peter Loftus July 26, 2012 A Pennsylvania appeals court handed a legal victory to Johnson & Johnson [JNJ] by upholding the dismissal of the state’s lawsuit accusing the drug maker of improperly marketing the antipsychotic drug Risperdal. The Commonwealth of […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-25356","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/25356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=25356"}],"version-history":[{"count":12,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/25356\/revisions"}],"predecessor-version":[{"id":25368,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/25356\/revisions\/25368"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=25356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=25356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=25356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![](\"http:\/\/1boringoldman.com\/images\/risperdal-7.gif\")
A Pennsylvania appeals court handed a legal victory to Johnson & Johnson [JNJ] by upholding the dismissal of the state’s lawsuit accusing the drug maker of improperly marketing the antipsychotic drug Risperdal. The Commonwealth of Pennsylvania had filed suit against J&J in 2007 seeking to recover expenses incurred by the state’s Medicaid program for reimbursing pharmacies for the purchase of Risperdal. The state alleged that J&J had promoted Risperdal for unapproved uses – also known as "off-label" uses – and misrepresented the drug’s safety risks.<\/p>\n![](\"http:\/\/1boringoldman.com\/images\/tmap-10.gif\")
Johnson & Johnson celebrated a rare victory Thursday in its multi-state court fights over marketing of the antipsychotic drug Risperdal.Pennsylvania’s Commonwealth Court upheld the decisions of two Philadelphia Common Pleas Court judges, who collectively, in effect, dismissed a state-sponsored suit alleging J&J’s Janssen subsidiary inappropriately profited from sales through the taxpayer-funded Medicaid program. "We are very pleased with the Pennsylvania Commonwealth Court’s unanimous decision that the trial judge was correct in granting our motion for non-suit, which effectively dismissed the case filed against the company in 2007," Janssen said in a statement.<\/p>\n